Sabin Vaccine Institute Archives | Page 3 of 3

Home / Posts tagged Sabin Vaccine Institute (Page 3)

Sabin Vaccine Institute’s Boost Community Prepares Immunization Professionals to Lead During the COVID-19 Crisis

WASHINGTON, June 16 (Korea Bizwire) — Amid the evolving global challenges posed by the novel coronavirus pandemic, immunization professionals must now grapple with deploying routine immunization services in a daunting and ever-shifting landscape. In a recent survey of 800 immunization professionals conducted by the World Health Organization (WHO), the Sabin Vaccine Institute (Sabin) and other [...]

Sabin Vaccine Institute Receives $10M Grant to Raise Confidence in Vaccines

WASHINGTON, March 12 (Korea Bizwire) — The Sabin Vaccine Institute (Sabin) today announced it has received a three-year grant valued at $10.4 million to strengthen vaccine acceptance. In 2019, the World Health Organization identified vaccine hesitancy – the reluctance or refusal to vaccinate despite the availability of vaccines – as one of the top 10 [...]

Sabin Vaccine Institute Strengthens Ebola Sudan and Marburg Vaccines Program with Additional NIAID Partnership

Washington, DC, March 5 (Korea Bizwire) — The Sabin Vaccine Institute (Sabin) today announced that it has partnered with the Vaccine Research Center (VRC), National Institute of Allergy and Infectious Diseases (NIAID), to manufacture prototype ChAd3 vectored Ebola Sudan and Marburg vaccines to be used for further clinical evaluation and outbreak preparedness and to potentially [...]

Sabin Vaccine Institute Receives $20.5 Million from BARDA with Potential of Up to $128 Million to Develop Ebola Sudan and Marburg Vaccines

WASHINGTON, Oct. 1 (Korea Bizwire) — The Sabin Vaccine Institute (Sabin) today announced a funding award of $20.5 million with options for an additional $107.5 million from the Biomedical Advanced Research and Development Authority (BARDA) within the U.S. Department of Health and Human Services. Under the terms of this agreement, the full program is expected [...]

GSK Grants Exclusive Technology License for Clinical-Stage Ebola Vaccines to Sabin Vaccine Institute

LONDON and WASHINGTON, Aug. 6 (Korea Bizwire) — GSK and the Sabin Vaccine Institute (Sabin) today announced exclusive agreements for Sabin to advance the development of the prophylactic candidate vaccines against the deadly Ebola Zaire, Ebola Sudan and the closely related, but lesser known, Marburg virus. No licensed vaccines against these three viruses are currently [...]